M Ohno1, Y Shimada2, M Satoh3, Y Kojima4, K Sakamoto4, S Hori5. 1. Intelligent Systems Laboratory, SECOM Co. Ltd, Mitaka, Tokyo, Japan; Medical Informatics Department, Juntendo University Graduate School, Bunkyo, Tokyo, Japan. Electronic address: m-ono@juntendo.ac.jp. 2. Intelligent Systems Laboratory, SECOM Co. Ltd, Mitaka, Tokyo, Japan; Medical Informatics Department, Juntendo University Graduate School, Bunkyo, Tokyo, Japan. 3. Medical Informatics Department, Juntendo University Graduate School, Bunkyo, Tokyo, Japan. 4. Department of Coloproctological Surgery, Juntendo University Graduate School, Bunkyo, Tokyo, Japan. 5. Department of Infection Control Science, Juntendo University Graduate School, Bunkyo, Tokyo, Japan; Medical Informatics Department, Juntendo University Graduate School, Bunkyo, Tokyo, Japan.
Abstract
BACKGROUND: Several reports have been published regarding cost increases attributable to surgical site infections (SSIs) in Europe and the USA. However, such studies have been limited in Japan. AIM: To evaluate the economic burden of colorectal SSIs on hospitals in Japan. METHODS: This study was undertaken at a Japanese university hospital. Amongst 265 patients who had undergone colorectal surgery in the Department of Coloproctological Surgery between November 2014 and March 2016, 16 patients who developed SSIs and could be allocated a diagnosis procedure combination code were selected as SSI cases. Individual SSI cases were matched to non-SSI cases based on a combination of surgical category, age band, sex, wound class, presence of stoma and risk index. Median length of stay (LOS) and piecework reference cost were compared between SSI episodes and non-SSI episodes. FINDINGS: The median LOS for patients with SSI and without SSI was 25.5 [interquartile range (IQR) 21.5-39.3] and 16.5 (IQR 12.5-18.5) days, respectively (P<0.01). The median piecework reference cost for patients with SSI and without SSI was ¥842,155 (IQR ¥716,423-1,388,968) and ¥575,795 (IQR ¥529,638-680,105), respectively (P<0.01). CONCLUSION: SSIs led to a significant increase in LOS and economic burden. Although the SSI episodes appear to be more profitable than the non-SSI episodes, the economic profit for SSI episodes was less than that for non-SSI episodes in the observation period, when opportunity costs were taken into account.
BACKGROUND: Several reports have been published regarding cost increases attributable to surgical site infections (SSIs) in Europe and the USA. However, such studies have been limited in Japan. AIM: To evaluate the economic burden of colorectal SSIs on hospitals in Japan. METHODS: This study was undertaken at a Japanese university hospital. Amongst 265 patients who had undergone colorectal surgery in the Department of Coloproctological Surgery between November 2014 and March 2016, 16 patients who developed SSIs and could be allocated a diagnosis procedure combination code were selected as SSI cases. Individual SSI cases were matched to non-SSI cases based on a combination of surgical category, age band, sex, wound class, presence of stoma and risk index. Median length of stay (LOS) and piecework reference cost were compared between SSI episodes and non-SSI episodes. FINDINGS: The median LOS for patients with SSI and without SSI was 25.5 [interquartile range (IQR) 21.5-39.3] and 16.5 (IQR 12.5-18.5) days, respectively (P<0.01). The median piecework reference cost for patients with SSI and without SSI was ¥842,155 (IQR ¥716,423-1,388,968) and ¥575,795 (IQR ¥529,638-680,105), respectively (P<0.01). CONCLUSION: SSIs led to a significant increase in LOS and economic burden. Although the SSI episodes appear to be more profitable than the non-SSI episodes, the economic profit for SSI episodes was less than that for non-SSI episodes in the observation period, when opportunity costs were taken into account.
Authors: Frank Werner Brennfleck; Tanja Bachmeier; Wolfgang Simet; Florian Zeman; Henrik Horst Gerhard Junger; Hans Jürgen Schlitt; Marc-Hendrik Dahlke; Stefan Martin Brunner Journal: Int Wound J Date: 2020-10-02 Impact factor: 3.315